Tenax Therapeutics (TENX) announced the appointment of Gillian Andor, MSc, as Vice President, Clinical Operations. Andor will lead the Company’s expanding Clinical Operations function in support of the ongoing Phase 3 program evaluating oral levosimendan for the treatment of pulmonary hypertension due to heart failure with preserved ejection fraction. She served most recently as Interim Head, Clinical Development Operations with Noema Pharma.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TENX: